More Evidence That Low-Dose Aspirin Ups Survival in CRC

This article originally appeared here.
Share this content:
More Evidence That Low-Dose Aspirin Ups Survival in CRC
More Evidence That Low-Dose Aspirin Ups Survival in CRC

FRIDAY, June 3, 2016 (HealthDay News) -- Colorectal cancer (CRC) patients who take low-dose aspirin may have better survival odds, according to a study published online May 31 the Journal of Clinical Oncology.

The findings are based on records from 23,162 Norwegian adults. They were all diagnosed with CRC between 2004 and 2011. More than one-quarter were prescribed daily low-dose aspirin for more than six months after their diagnosis. And, most had been taking aspirin before their diagnosis.

The researchers found that, overall, 67.1 percent of aspirin users were still alive after about three years. That compared with 57.7 percent of nonusers. After adjustment for factors such as age, severity of cancer, and whether patients were taking other particular medications, the survival benefit for aspirin users remained. The benefit was concentrated among patients who'd been taking aspirin before their diagnosis: They were 23 percent less likely to die of CRC -- and 14 percent less likely to die of any cause -- than patients who did not use aspirin at all.

"Aspirin use after the diagnosis of CRC is independently associated with improved CRC-specific survival and overall survival," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

SABCS: Artificial Intelligence May Aid Doctors in Breast ...

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

SABCS: Scalp-Cooling System Can Reduce Chemo-Related Hair Loss

Devices reduce blood flow to hair follicles during chemotherapy treatments

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

SABCS: Aromatase Inhibitors Tied to Reduced Endothelial Function

Women on aromatase inhibitors exhibit less elasticity in their blood vessels

is free, fast, and customized just for you!

Already a member?

Sign In Now »